Gene Silencing

Gene Silencing encompasses techniques reducing or eliminating specific gene expression without altering DNA sequences, employing diverse mechanisms including RNA interference, antisense oligonucleotides, small interfering RNAs, microRNAs, or epigenetic modifications. Gene silencing offers advantages over gene knockout including reversibility, dose-dependent effects, and applicability to post-developmental stages.

The pharmaceutical industry pursues gene silencing as both research tool and therapeutic modality. RNA interference therapeutics employ small interfering RNAs reducing target gene expression and treating diseases from genetic disorders to viral infections. Antisense oligonucleotides represent clinically validated gene silencing with multiple approved products addressing diverse conditions. Target validation employs transient gene silencing assessing phenotypic consequences of expression reduction. Chemical modifications including phosphorothioate backbones and 2'-O-methyl sugars enhance oligonucleotide stability and therapeutic potential. Delivery approaches include lipid nanoparticles enabling systemic delivery, conjugates directing tissue-specific uptake, and local administration. As delivery technologies improve and understanding deepens, gene silencing therapeutics expand addressing previously undruggable targets.